Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Fda crawled time : 01:00 save search
Akebia Receives FDA Approval of Vafseo® (vadadustat) Tablets for the Treatment of Anemia due to Chronic Kidney Disease in Adult Patients on Dialysis
Published: 2024-03-28 (Crawled : 01:00) - prnewswire.com
AKBA | $1.365 0.37% 0.37% 2.1M
|
Health Technology
|
| O: 10.27%
H: 0.4%
C: -25.91%
vafseo fda disease kidney anemia approval treatment dialysis
U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Epcoritamab (EPKINLY®) for Difficult-to-Treat Relapsed or Refractory Follicular Lymphoma
Published: 2024-02-27 (Crawled : 01:00) - globenewswire.com
GNMSF | News | $289.67 3.83% 5.3K
|
Health Technology
|
| O: -0.28%
H: 1.46%
C: 1.46%
ABBV | News | $169.54 0.98% -0.91% 4.1M
|
Health Technology
|
| O: 0.13%
H: 0.0%
C: 0.0%
GMAB | News | $28.54 -1.48% -1.51% 560K
|
Health Technology
|
| O: -1.6%
H: 1.11%
C: 0.41%
epkinly fda license review application
Heron Therapeutics Announces FDA Approval of ZYNRELEF® Indication Expansion to Include Additional Orthopedic and Soft Tissue Procedures
Published: 2024-01-24 (Crawled : 01:00) - prnewswire.com
HRTX M | $2.805 8.3% 7.66% 6.6M
|
Health Technology
|
| O: 5.91%
H: 12.45%
C: 12.23%
zynrelef fda approval expansion therapeutics
Global Rare Hemophilia Factors Market Analysis Report 2023-2030 - Tailored Factor Concentrates Gain FDA Approval, Fueling Rare Hemophilia Factors Market Growth
Published: 2023-10-03 (Crawled : 01:00) - prnewswire.com
PFE | News 4 | $26.32 0.23% 0.0% 24M
|
Health Technology
|
| O: -0.29%
H: 0.8%
C: 0.18%
fda rare report global growth market
WuXi Biologics Congratulates Amicus Therapeutics on U.S. FDA Approval for New Treatment for Pompe Disease
Published: 2023-10-02 (Crawled : 01:00) - prnewswire.com
FOLD 4 | $10.7 -1.11% -1.12% 3.2M
|
Health Technology
|
| O: -0.66%
H: 0.66%
C: -8.69%
fda disease approval treatment therapeutics
Day One Announces Updated FIREFLY-1 Data for Tovorafenib and Completion of Rolling NDA Submission to FDA for Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG)
Published: 2023-09-12 (Crawled : 01:00) - globenewswire.com
DAWN S | $16.65 8.26% 7.63% 6.6M
|
Professional, Scientific, and T...
|
| O: 0.42%
H: 5.02%
C: 2.72%
day fda one submission
Medtronic issues statement on the FDA Circulatory Systems Devices Advisory Panel vote for the Symplicity Spyral Renal Denervation System
Published: 2023-08-24 (Crawled : 01:00) - prnewswire.com
MDT | $81.29 0.89% 0.0% 5.2M
|
Health Technology
|
| O: -2.61%
H: 0.0%
C: 0.0%
fda renal system
Everest Medicines Announces Partner Calliditas Therapeutics Receives FDA Priority Review for Full Approval of Nefecon® for the Treatment of IgA Nephropathy
Published: 2023-08-21 (Crawled : 01:00) - prnewswire.com
CALT | $18.0825 -1.71% 1.9K
|
Health Technology
|
| O: 8.17%
H: 1.41%
C: -1.69%
nefecon fda nephropathy approval review treatment therapeutics
HUTCHMED Completes Rolling Submission of NDA to U.S. FDA for Fruquintinib for the Treatment of Refractory Metastatic Colorectal Cancer
Published: 2023-03-31 (Crawled : 01:00) - globenewswire.com
TAK | News | $13.38 0.15% 0.9% 1.7M
|
Health Technology
|
| O: 0.0%
H: 0.92%
C: 0.8%
HCM | $18.2 7.44% 6.92% 120K
|
Health Technology
|
| O: -1.19%
H: 2.04%
C: -1.66%
fda cancer treatment submission
Biogen Provides Update on FDA Advisory Committee Meeting on Tofersen for SOD1-ALS
Published: 2023-03-23 (Crawled : 01:00) - globenewswire.com
BIIB | $193.18 -0.48% -0.48% 1.4M
|
Health Technology
|
| O: 0.62%
H: 1.75%
C: 0.89%
fda update meeting
Innoviva Announces FDA Advisory Committee Meeting to Review Sulbactam-Durlobactam (SUL-DUR), an Investigational Targeted Antibiotic
Published: 2023-03-13 (Crawled : 01:00) - biospace.com/
INVA | $15.16 1.54% 1.52% 1.5M
|
Health Technology
|
| O: -0.46%
H: 3.63%
C: 1.58%
fda meeting review
QuidelOrtho Receives De Novo FDA Authorization for Sofia® 2 SARS Antigen+ FIA
Published: 2023-03-08 (Crawled : 01:00) - biospace.com/
QDEL | News 4 | $40.43 3.45% 3.34% 1.2M
|
Health Technology
|
| O: 0.02%
H: 0.91%
C: -2.32%
sofia fda authorization
FDA Accepts Mesoblast’s Resubmission of the Biologic License Application for Remestemcel-L In Children with Steroid-Refractory Acute Graft Versus Host Disease as a Complete Response and Sets Goal Date of August 2, 2023
Published: 2023-03-08 (Crawled : 01:00) - globenewswire.com
MESO | $5.97 7.96% 7.37% 630K
|
Health Technology
|
| O: 10.89%
H: 18.45%
C: 11.61%
fda disease children application resubmission license response
BioMarin Provides Update on FDA Review of ROCTAVIAN™ (Valoctocogene Roxaparvovec) Gene Therapy for Adults with Severe Hemophilia A
Published: 2023-03-07 (Crawled : 01:00) - prnewswire.com
BMRN | $92.06 2.87% 2.79% 1.3M
|
Health Technology
|
| O: -0.88%
H: 2.17%
C: -0.05%
fda review therapy update
Verrica Pharmaceuticals Announces FDA Acceptance of Filing of Resubmitted NDA for VP-102 for the Treatment of Molluscum Contagiosum
Published: 2023-02-27 (Crawled : 01:00) - globenewswire.com
VRCA | $6.85 0.88% 0.88% 86K
|
Health Technology
|
| O: 0.0%
H: 7.76%
C: 1.97%
vp-102 molluscum treatment fda pharmaceuticals
Everest Medicines' Licensing Partner Pfizer Announces FDA and EMA Acceptance of Etrasimod Regulatory Submissions for Ulcerative Colitis
Published: 2022-12-22 (Crawled : 01:00) - prnewswire.com
PFE | News 4 | $26.32 0.23% 0.0% 24M
|
Health Technology
|
| O: -0.48%
H: 0.56%
C: 0.45%
fda ema ulcerative colitis
AVITA Medical Announces FDA Breakthrough Device Designations for the RECELL® System
Published: 2022-11-04 (Crawled : 01:00) - globenewswire.com
RCEL | $8.98 5.03% 4.79% 200K
|
Health Technology
|
| O: 3.83%
H: 1.64%
C: 1.23%
recell fda device system
Syros Receives FDA Orphan Drug Designation for SY-5609 for the Treatment of Pancreatic Cancer
Published: 2022-09-13 (Crawled : 01:00) - biospace.com/
SYRS | $5.17 3.61% 3.48% 170K
|
Health Technology
|
| O: 21.87%
H: 3.93%
C: -13.94%
sy-5609 treatment fda designation drug cancer pancreatic
ImmuCell Receives Technical Section Incomplete Letter from FDA Pertaining to Re-Tain®
Published: 2022-07-28 (Crawled : 01:00) - globenewswire.com
ICCC | $5.03 0.2% 280
|
Health Technology
|
| O: -2.32%
H: 4.62%
C: 4.27%
tain fda
Beyond Air’s LungFit® PH Receives FDA Approval to Treat Term and Near-Term Neonates with Hypoxic Respiratory Failure
Published: 2022-06-28 (Crawled : 01:00) - biospace.com/
XAIR | $1.205 -0.41% -0.41% 360K
|
Technology Services
|
| O: -0.16%
H: 1.44%
C: -7.67%
lungfit fda respiratory approval
Gainers vs Losers
| 78% | 22% |
Top 10 Gainers
MTTR | News 4 | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 1.1M
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.